Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05791695 · ClinicalTrials.gov registry record
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 155,413
- Enrollment target
NCT05791695 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 155,413 participants.
The verdict
NCT05791695 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 155,413 participants
- Enrollment target
Study Summary
Specific study objectives include: * To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually). * To estimate the annual and quarterly incidence of intraocular inflammation (IOI) and suspected endophthalmitis for aflibercept user injections by aflibercept dispensing device. Secondary objectives • To estimate the annual incidence of IOI and suspected endophthalmitis for aflibercept user injections by dispensing device, stratified by indication for use, history of IOI, and provider characteristics.
Interventions
- OTHER Non Applicable
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155,413 participants |
| Start Date | 2022-09-16 |
| Est. Completion | 2023-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05791695
The ClinicalTrials.gov registry entry for NCT05791695 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 155,413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non Applicable is the first listed.
NCT05791695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05791695 about?
NCT05791695 is a clinical study titled "A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022". Specific study objectives include: * To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually). * To estimate the annual and quarterly incidence of intraocular inf...
What is the current status of trial NCT05791695?
This trial is currently completed. The enrollment target is 155,413 participants. The study started on 2022-09-16. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT05791695?
The interventions under investigation include: Non Applicable (OTHER).
Who is sponsoring clinical trial NCT05791695?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.